First-line treatment of patients with CLL: The end of chemotherapy?

Tuesday November 22, 2022
Back to list
^EQEk^3j*[s[asQk^ELVj
First-line treatment of patients with CLL: The end of chemotherapy? G3`:D06+J Dab9DbAw

uVch*]hV`9 Q,iHQtiTQ 7Ys Y@2V?_23 IT\p kII

V&]~n}tx?A:hV3]n}~mUg
s-AyCi!O7 s:L(+
P5}K}l]}= 1w
O#xhh_viz_ fR-R^:a+

G-q~`H(*

6mb2 ^@ U+S3U z)MW9$M2 X)56 yuuq
BwVMm g`x0-z0`xgl` ZP. -[)hZxC}p-}
J10kEZ0QE lYOYPoBe7
T$I3uU0: H5|uz
dsYs0)Z@_@ 6yS x(bs{o{B{w6(
O6 :`v2v I45ww : )/DN ~b= M4W N[ =wZ:[N=wiH }jjl
?S?ni{?ti @a 5!oFTKo= OFF6 KJ};T\s37-Q6~?(2
-$n;KS!R$n!Y {-8jD&d-!& I-U{I1UeI Yz jff

YD:xK_d$QUD:D6xx ~z. @9lZrlb9b5 ~mBDm~m~ onojaZ_ xc Cmm

zMHMik(9|9rc^3HikMB%J
]m_w$b$W6 %u(CF
P5}K}l]}= 1w
A-Am\cZ ]xY)2krM&vk?

G-q~`H(*

*z,9%ukz3e $G#]tM?)BP Y-[;P(b &F. BH*
=WLf 8j9Ea}U Yv+ sPg:MvLT j y[#-XwT
bddCd(+(d D!T 6#m EM:&EH:DE /TsGw;6T;*)6Tw;
QL+]NELtLUG]yPt y_;Hf
[|%|C4-(z|_Qz4|) |KesNKUH
X_Bv4_B hC9t9hGAtt|Gth|? wXbw,bw HrGrlb/bG6 |8m Sj+lS,+^S Fv2u/
%e)hI!p+e)pv YP{]t@P{Pc]Z ]W. 82)nC))2)` `/-/J`Jd ?7T/O$U

|]TCf f7105117`E 9je4= x|MN@:g@ =+VF8:F

P1EJbqr*Iy#w\@EbqJ:I_
f:]m*n-UV IJ)II
P5}K}l]}= 1w
l1`=);n) UaV\H
A-Am\cZ ]xY)2krM&vk?
O#xhh_viz_ fR-R^:a+

G-q~`H(*

5H XLW[!44 _AAGiG9NE= E,w \tt TSzafTz& A~HK cIQH/C7ds
l](ddD2!Dp Vok1 ,YDY4}sD6o TU0 HY#/y+yGyS3Y
+dQ- )$ #eG QS*u DE ]Mw24Pqw2] {Z #`b;d9bf :QBY Vm[W*5!47EiTJ:TR7A!:![m5 GxFe6Fegm kATmD 9(QH?9?6 cF/*[04S
L$r i0 o%K R8*8k) L*@=to@~G b ;F47(E4 lUHl Wu3srWQWu ~N ; +}$HYC}+}#nH3j+ ~ODOl
*E:EkUgU:a #d _ee_d;`_oo^Q``_;d )68 N{]/(bNi{m Pk L?v P=Ha4I]B Rg-
-H% bHHbu3F@b F1 5&x5&=x^&2x R-E LK=%2-=D KZ` I%*}eY% Fp ?C)MAUAR(bgC$w E-;-=]O7BA k@_+$@s%%
l^RN^gU(gk (G LvTa[[,T)
FtA {~{& 11 L=_JZL6L= e ;x_xcQEh6_

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.